These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. Zinzani PL; Santoro A; Gritti G; Brice P; Barr PM; Kuruvilla J; Cunningham D; Kline J; Johnson NA; Mehta-Shah N; Manley T; Francis S; Sharma M; Moskowitz AJ J Clin Oncol; 2019 Nov; 37(33):3081-3089. PubMed ID: 31398081 [TBL] [Abstract][Full Text] [Related]
28. Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study. Stamatoullas A; Ghesquières H; Feugier P; André M; Le Bras F; Gac AC; Borel C; Gastinne T; Quittet P; Morschhauser F; Ribrag V; Guidez S; Nicolas-Virelizier E; Berriolo-Riedinger A; Vander Borght T; Edeline V; Brice P Leuk Lymphoma; 2022 Dec; 63(13):3063-3071. PubMed ID: 35975738 [TBL] [Abstract][Full Text] [Related]
29. Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin. Faulk KE; Sopfe JM; Campbell K; Liptzin DR; Liu AK; Franklin ARK; Cost CR Br J Haematol; 2018 Oct; 183(2):251-256. PubMed ID: 30198571 [TBL] [Abstract][Full Text] [Related]
30. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014 [TBL] [Abstract][Full Text] [Related]
31. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience. Massaro F; Pavone V; Stefani PM; Botto B; Pulsoni A; Patti C; Cantonetti M; Visentin A; Scalzulli PR; Rossi A; Galimberti S; Cimminiello M; Gini G; Musso M; Sorio M; Arcari A; Zilioli VR; Luppi M; Mannina D; Fabbri A; Pietrantuono G; Annibali O; Tafuri A; Prete E; Mulè A; Barbolini E; Marcheselli L; Luminari S; Merli F Hematol Oncol; 2022 Feb; 40(1):31-39. PubMed ID: 34694649 [TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma. Kort J; Chidiac A; El Sayed R; Massoud R; Nehme R; Bazarbachi A; El-Cheikh J Leuk Lymphoma; 2020 Jul; 61(7):1732-1735. PubMed ID: 32090673 [TBL] [Abstract][Full Text] [Related]
33. Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies. Forero-Torres A; Fanale M; Advani R; Bartlett NL; Rosenblatt JD; Kennedy DA; Younes A Oncologist; 2012; 17(8):1073-80. PubMed ID: 22855426 [TBL] [Abstract][Full Text] [Related]
34. Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study. Akay OM; Ozbalak M; Pehlivan M; Yildiz B; Uzay A; Yigenoglu TN; Elverdi T; Kaynar L; Ayyildiz O; Yonal Hindilerden I; Goksoy HS; Izmir Guner S; Gunes AK; Sonmez M; Kurt Yuksel M; Civriz Bozdag S; Ozkurt ZN; Toptas T; Dogu MH; Salim O; Saydam G; Yavasoglu I; Ayli M; Ozet G; Albayrak M; Birtas Atesoglu E; Toprak SK; Yildirim R; Mehtap O; Kalayoglu Besisik S; Nalcaci M; Altuntas F; Ferhanoglu B Hematol Oncol; 2021 Oct; 39(4):498-505. PubMed ID: 34171130 [TBL] [Abstract][Full Text] [Related]
36. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma. Martínez C; de Haro ME; Romero S; Gutiérrez A; Domingo-Domènech E; González-Rodríguez AP; Zeberio I; Martínez-Badas MP; Rodríguez-Izquierdo A; Carpio C; Bastos-Oreiro M; Hernández-Rivas JÁ; Vallansot R; Kelleher N; Díaz-Gálvez FJ; Torrado T; Pereira A; García-Sanz R; Ann Hematol; 2023 Feb; 102(2):429-437. PubMed ID: 36370191 [TBL] [Abstract][Full Text] [Related]
37. Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma. Spathas N; Belia M; Giannikos T; Arapaki M; Efstathopoulou M; Tsourouflis G; Gainaru G; Asimakopoulos J; Tsaftaridis P; K Angelopoulou M; Plata E; Konstantopoulos K; P Vassilakopoulos T J BUON; 2019; 24(6):2483-2489. PubMed ID: 31983123 [TBL] [Abstract][Full Text] [Related]
38. Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era. Graf SA; Gopal AK Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):151-7. PubMed ID: 25696848 [TBL] [Abstract][Full Text] [Related]
39. [Analysis of 10 cases of brentuximab vedotin combined with chemotherapy in the treatment of children with refractory and or relapsed classic Hodgkin lymphoma]. Li N; Li Y; Zhou CJ; Huang S; Jin L; Yang J; Shao MM; Sun H; Wang XL; Duan YL Zhonghua Er Ke Za Zhi; 2024 Aug; 62(8):775-779. PubMed ID: 39039881 [No Abstract] [Full Text] [Related]
40. Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience. Moretti M; Liberati AM; Rigacci L; Puccini B; Pulsoni A; Gini G; Galieni P; Fabbri A; Cantonetti M; Pavone V; Bolis S; Botto B; Renzi D; Falchi L Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):198-204. PubMed ID: 34690088 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]